Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Sells $1,310,820.00 in Stock

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. This trade represents a 31.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Sarepta Therapeutics Stock Down 4.4 %

Shares of NASDAQ:SRPT opened at $120.25 on Thursday. The firm has a market cap of $11.49 billion, a PE ratio of 96.20 and a beta of 0.77. The company has a fifty day simple moving average of $123.46 and a 200 day simple moving average of $131.44. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12-month low of $89.92 and a 12-month high of $173.25.

Institutional Investors Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Envestnet Portfolio Solutions Inc. acquired a new position in Sarepta Therapeutics in the second quarter worth about $201,000. Fifth Third Bancorp lifted its holdings in Sarepta Therapeutics by 22.0% during the 2nd quarter. Fifth Third Bancorp now owns 1,220 shares of the biotechnology company’s stock worth $193,000 after buying an additional 220 shares during the last quarter. Fifth Third Wealth Advisors LLC acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $607,000. Louisiana State Employees Retirement System bought a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at approximately $4,219,000. Finally, New York State Teachers Retirement System acquired a new stake in shares of Sarepta Therapeutics during the 2nd quarter valued at approximately $12,051,000. Institutional investors own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

SRPT has been the topic of several research reports. Needham & Company LLC cut their price target on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a “buy” rating on the stock in a report on Wednesday, November 27th. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Jefferies Financial Group started coverage on Sarepta Therapeutics in a report on Monday, October 21st. They issued a “buy” rating and a $165.00 price target for the company. William Blair upgraded Sarepta Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Guggenheim upped their target price on Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.71.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.